PDF下载 ( 1897 KB)
吡咯生物碱相关肝窦阻塞综合征发病机制的研究进展
DOI: 10.3969/j.issn.1001-5256.2021.04.052
利益冲突声明：所有作者均声明不存在利益冲突。
作者贡献声明：刘文成负责资料分析、撰写论文；李琰参与资料分析、修改论文；常冰负责拟定写作思路、指导撰写文章并最后定稿。
Research advances in the pathogenesis of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome
-
摘要: 吡咯生物碱诱导的肝窦阻塞综合征主要原因为摄入了含吡咯生物碱的中草药或食品。从药物因素、宿主因素、影响因素三个方面，回顾了近年来吡咯生物碱及其代谢产物参与疾病发生发展机制的研究进展。认为吡咯生物碱相关肝窦阻塞综合征的发病机制复杂、影响因素较多，部分患者预后较差，且发病机制尚未十分明确，有必要进一步深入研究。Abstract: Pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome (PA-HSOS) is a type of hepatic sinusoidal obstruction syndrome mainly caused by the intake of Chinese herbal medicine or food containing pyrrolizidine alkaloids. This article reviews the recent research advances in the mechanism of action of pyrrolizidine alkaloids and their metabolites in disease development and progression from the aspects of drug factors, host factors, and influencing factors. It is pointed out that PA-HSOS has complex pathogenesis and various influencing factors, and some patients tend to have a poor prognosis; its pathogenesis remains unclear and needs further in-depth studies.
-
[1] Cooperative Group for Hepatic and Gall Diseases, Chinese Society of Gastroenterology, Chinese Medical Association. Expert consensus on diagnosis and treatment of pyrrolidine alkaloids-related sinusoidal obstruction syndrome (2017, Nanjing)[J]. J Clin Hepatol, 2017, 33(9): 1627-1637. (in Chinese) DOI: 10.3969/j.issn.1001-5256.2017.09.003中华医学会消化病学分会肝胆疾病协作组. 吡咯生物碱相关肝窦阻塞综合征诊断和治疗专家共识意见(2017年, 南京)[J]. 临床肝胆病杂志, 2017, 33(9): 1627-1637. DOI: 10.3969/j.issn.1001-5256.2017.09.003 [2] MOHTY M, MALARD F, ABECASSIS M, et al. Revised diagnosis and severity criteria for sinusoidal obstruction syndrome/veno-occlusive disease in adult patients: A new classification from the European Society for Blood and Marrow Transplantation[J]. Bone Marrow Transplant, 2016, 51(7): 906-912. DOI: 10.1038/bmt.2016.130 [3] WELDEAREGAY KT, GEBREKIDAN MG, GEZAHEGNE AA. Health impact of hepatic-venous-occlusive disease in a small town in Ethiopia-Case study from Tahtay koraro district in Tigray region, 2017[J]. PLoS One, 2019, 14(11): e0224659. DOI: 10.1371/journal.pone.0224659 [4] PENG C, ZHANG X, ZHANG F, et al. Clinical efficacy and safety of anticoagulation therapy for Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: A retrospective multicenter cohort study[J]. Eur J Gastroenterol Hepatol, 2020, 32(9): 1168-1178. DOI: 10.1097/MEG.0000000000001630 [5] ZHUGE Y, LIU Y, XIE W, et al. Expert consensus on the clinical management of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol, 2019, 34(4): 634-642. DOI: 10.1111/jgh.14612 [6] OPLATOWSKA M, ELLIOTT CT, HUET AC, et al. Development and validation of a rapid multiplex ELISA for pyrrolizidine alkaloids and their N-oxides in honey and feed[J]. Anal Bioanal Chem, 2014, 406(3): 757-770. DOI: 10.1007/s00216-013-7488-7 [7] YANG XQ, YE J, LI X, et al. Pyrrolizidine alkaloids-induced hepatic sinusoidal obstruction syndrome: Pathogenesis, clinical manifestations, diagnosis, treatment, and outcomes[J]. World J Gastroenterol, 2019, 25(28): 3753-3763. DOI: 10.3748/wjg.v25.i28.3753 [8] RUAN J, YANG M, FU P, et al. Metabolic activation of pyrrolizidine alkaloids: Insights into the structural and enzymatic basis[J]. Chem Res Toxicol, 2014, 27(6): 1030-1039. DOI: 10.1021/tx500071q [9] RUAN J, GAO H, LI N, et al. Blood pyrrole-protein adducts—a biomarker of pyrrolizidine alkaloid-induced liver injury in humans[J]. J Environ Sci Health C Environ Carcinog Ecotoxicol Rev, 2015, 33(4): 404-421. DOI: 10.1080/10590501.2015.1096882 [10] MA J, XIA Q, FU PP, et al. Pyrrole-protein adducts-A biomarker of pyrrolizidine alkaloid-induced hepatotoxicity[J]. J Food Drug Anal, 2018, 26(3): 965-972. DOI: 10.1016/j.jfda.2018.05.005 [11] EBMEYER J, BEHREND J, LORENZ M, et al. Pyrrolizidine alkaloid-induced alterations of prostanoid synthesis in human endothelial cells[J]. Chem-Biol Interact, 2019, 298: 104-111. DOI: 10.1016/j.cbi.2018.11.007 [12] HARB R, XIE G, LUTZKO C, et al. Bone marrow progenitor cells repair rat hepatic sinusoidal endothelial cells after liver injury[J]. Gastroenterology, 2009, 137(2): 704-712. DOI: 10.1053/j.gastro.2009.05.009 [13] LI YH, TAI WC, XUE JY, et al. Proteomic study of pyrrolizidine alkaloid-induced hepatic sinusoidal obstruction syndrome in rats[J]. Chem Res Toxicol, 2015, 28(9): 1715-1727. DOI: 10.1021/acs.chemrestox.5b00113 [14] NAKAMURA K, HATANO E, NARITA M, et al. Sorafenib attenuates monocrotaline-induced sinusoidal obstruction syndrome in rats through suppression of JNK and MMP-9[J]. J Hepatol, 2012, 57(5): 1037-1043. DOI: 10.1016/j.jhep.2012.07.004 [15] HUANG Z, CHEN M, WEI M, et al. Liver inflammatory injury initiated by DAMPs-TLR4-MyD88/TRIF-NFκB signaling pathway is involved in monocrotaline-induced HSOS[J]. Toxicol Sci, 2019, 172(2): 385-397. DOI: 10.1093/toxsci/kfz193 [16] ITO Y. A novel therapeutic strategy for liver sinusoidal obstruction syndrome[J]. J Gastroenterol Hepatol, 2009, 24(6): 933-934. DOI: 10.1111/j.1440-1746.2009.05839.x [17] DELEVE LD, WANG X, TSAI J, et al. Sinusoidal obstruction syndrome (veno-occlusive disease) in the rat is prevented by matrix metalloproteinase inhibition[J]. Gastroenterology, 2003, 125(3): 882-890. DOI: 10.1016/S0016-5085(03)01056-4 [18] EZZAT T, VAN DEN BROEK MAJ, DAVIES N, et al. The flavonoid monoHER prevents monocrotaline-induced hepatic sinusoidal injury in rats[J]. J Surg Oncol, 2012, 106(1): 72-78. DOI: 10.1002/jso.23046 [19] OKUNO M, HATANO E, NAKAMURA K, et al. Regorafenib suppresses sinusoidal obstruction syndrome in rats[J]. J Surg Res, 2015, 193(2): 693-703. DOI: 10.1016/j.jss.2014.08.052 [20] HSIA DA, MITRA SK, HAUCK CR, et al. Differential regulation of cell motility and invasion by FAK[J]. J Cell Biol, 2003, 160(5): 753-767. DOI: 10.1083/jcb.200212114 [21] HIBATA K, KIKKAWA F, NAWA A, et al. Bothfocal adhesion kinase and c-Ras are required for the enhanced matrixmetalloproteinase 9 secretion by fibronectin in ovarian cancer cells[J]. CancerRes, 1998, 58: 900-903. [22] MIN L, HE B, HUI L. Mitogen-activated protein kinases in hepatocellular carcinoma development[J]. Semin Cancer Biol, 2011, 21(1): 10-20. DOI: 10.1016/j.semcancer.2010.10.011 [23] CHOJKIER M. Hepatic sinusoidal-obstruction syndrome: Toxicity of pyrrolizidine alkaloids[J]. J Hepatol, 2003, 39(3): 437-446. DOI: 10.1016/S0168-8278(03)00231-9 [24] YANG M, RUAN J, FU PP, et al. Cytotoxicity of pyrrolizidine alkaloid in human hepatic parenchymal and sinusoidal endothelial cells: Firm evidence for the reactive metabolites mediated pyrrolizidine alkaloid-induced hepatotoxicity[J]. Chem-Biol Interact, 2016, 243: 119-126. DOI: 10.1016/j.cbi.2015.09.011 [25] DUSEMUND B, NOWAK N, SOMMERFELD C, et al. Risk assessment of pyrrolizidine alkaloids in food of plant and animal origin[J]. Food Chem Toxicol, 2018, 115: 63-72. DOI: 10.1016/j.fct.2018.03.005 [26] WANG X, KANEL GC, DELEVE LD. Support of sinusoidal endothelial cell glutathione prevents hepatic veno-occlusive disease in the rat[J]. Hepatology, 2000, 31(2): 428-434. DOI: 10.1002/hep.510310224 [27] CONOTTE R, COLET JM. A metabonomic evaluation of the monocrotaline-induced sinusoidal obstruction syndrome (SOS) in rats[J]. Toxicol Appl Pharmacol, 2014, 276(2): 147-156. DOI: 10.1016/j.taap.2014.02.008 [28] HESSEL-PRAS S, BRAEUNING A, GUENTHER G, et al. The pyrrolizidine alkaloid senecionine induces CYP-dependent destruction of sinusoidal endothelial cells and cholestasis in mice[J]. Arch Toxicol, 2020, 94(1): 219-229. DOI: 10.1007/s00204-019-02582-8 [29] YANG M, RUAN J, GAO H, et al. First evidence of pyrrolizidine alkaloid N-oxide-induced hepatic sinusoidal obstruction syndrome in humans[J]. Arch Toxicol, 2017, 91(12): 3913-3925. DOI: 10.1007/s00204-017-2013-y [30] NARITA M, HATANO E, TAMAKI N, et al. Dai-kenchu-to attenuates rat sinusoidal obstruction syndrome by inhibiting the accumulation of neutrophils in the liver[J]. J Gastroenterol Hepatol, 2009, 24(6): 1051-1057. DOI: 10.1111/j.1440-1746.2009.05795.x [31] ZHANG J, SHENG Y, SHI L, et al. Quercetin and baicalein suppress monocrotaline-induced hepatic sinusoidal obstruction syndrome in rats[J]. Eur J Pharmacol, 2017, 795: 160-168. DOI: 10.1016/j.ejphar.2016.12.015 [32] ZHENG Z, SHI L, SHENG Y, et al. Chlorogenic acid suppresses monocrotaline-induced sinusoidal obstruction syndrome: The potential contribution of NFκB, Egr1, Nrf2, MAPKs and PI3K signals[J]. Environ Toxicol Pharmacol, 2016, 46: 80-89. DOI: 10.1016/j.etap.2016.07.002 [33] VALLA DC, CAZALS-HATEM D. Sinusoidal obstruction syndrome[J]. Clin Res Hepatol Gastroenterol, 2016, 40(4): 378-385. DOI: 10.1016/j.clinre.2016.01.006 [34] RUBBIA-BRANDT L. Sinusoidal obstruction syndrome[J]. Clin Liver Dis, 2010, 14(4): 651-668. DOI: 10.1016/j.cld.2010.07.009 [35] DELEVE LD, WANG X, GUO Y. Sinusoidal endothelial cells prevent rat stellate cell activation and promote reversion to quiescence[J]. Hepatology, 2008, 48(3): 920-930. DOI: 10.1002/hep.22351 [36] GVNTHER S, PERROS F, RAUTOU PE, et al. Understanding the similarities and differences between hepatic and pulmonary veno-occlusive disease[J]. Am J Pathol, 2019, 189(6): 1159-1175. DOI: 10.1016/j.ajpath.2019.02.007 [37] HIRATA M, TAJIMA H, MIYASHITA T, et al. Extravasated platelet aggregation in the livers of rats with drug-induced hepatic sinusoidal obstruction syndrome[J]. Mol Med Rep, 2017, 15(5): 3147-3152. DOI: 10.3892/mmr.2017.6407 [38] NARMADA BC, CHIA SM, TUCKER-KELLOGG L, et al. HGF regulates the activation of TGF-β1 in rat hepatocytes and hepatic stellate cells[J]. J Cell Physiol, 2013, 228(2): 393-401. DOI: 10.1002/jcp.24143 [39] GRESSNER AM, WEISKIRCHEN R. Modern pathogenetic concepts of liver fibrosis suggest stellate cells and TGF-beta as major players and therapeutic targets[J]. J Cell Mol Med, 2006, 10(1): 76-99. DOI: 10.1111/j.1582-4934.2006.tb00292.x [40] ZHU H, CHU Y, HUO J, et al. Effect of prednisone on transforming growth factor-β1, connective tissue growth factor, nuclear factor-κBp65 and tumor necrosis factor-α expression in a murine model of hepatic sinusoidal obstruction syndrome induced by Gynura segetum[J]. Hepatol Res, 2011, 41(8): 795-803. DOI: 10.1111/j.1872-034X.2011.00830.x [41] SUN K, WANG Q, HUANG XH. PPAR gamma inhibits growth of rat hepatic stellate cells and TGF beta-induced connective tissue growth factor expression[J]. Acta Pharmacol Sin, 2006, 27(6): 715-723. DOI: 10.1111/j.1745-7254.2006.00299.x -
本文二维码
计量
- 文章访问数: 656
- HTML全文浏览量: 153
- PDF下载量: 51
- 被引次数: 0
下载:
